文献类型：期刊文献

英文题名：Acupoint Injection of Onabotulinumtoxin A for Migraines

作者：Hou, Min[1,2];Xie, Jun-Fan[1];Kong, Xiang-Pan[1,3];Zhang, Yi[4];Shao, Yu-Feng[1];Wang, Can[1];Ren, Wen-Ting[1];Cui, Guang-Fu[1];Xin, Le[1];Hou, Yi-Ping[1]

第一作者：Hou, Min;侯敏

通信作者：Hou, YP[1]

机构：[1]Lanzhou Univ, Sch Basic Med Sci, Dept Neurosci Anat Histol & Embryol, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou 730000, Peoples R China;[2]Gansu Univ Tradit Chinese Med, Dept Anat, Lanzhou 730000, Peoples R China;[3]Hunan Normal Univ, Sch Med, Dept Human Anat, Changsha 410013, Hunan, Peoples R China;[4]Gansu Prov People Hosp, Dept Neurol & Pain Treatment, Lanzhou 730000, Peoples R China

第一机构：Lanzhou Univ, Sch Basic Med Sci, Dept Neurosci Anat Histol & Embryol, Key Lab Preclin Study New Drugs Gansu Prov, Lanzhou 730000, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Sch Basic Med Sci, Dept Neurosci Anat Histol & Embryol, Key Lab Preclin Study New Drugs Gansu Prov, 199 Donggang Xi Rd, Lanzhou 730000, Peoples R China.

年份：2015

卷号：7

期号：11

起止页码：4442

外文期刊名：TOXINS

收录：;Scopus(收录号：2-s2.0-84946068110);WOS:【SCI-EXPANDED(收录号:WOS:000365647700005)】；

基金：This work was supported by Scientific and Technique Support Project of Gansu Province (090NKCA112), China.

语种：英文

外文关键词：botulinum toxin type A; migraine; fixed-sites injection; acupoint-sites injection; randomized and placebo-controlled trial

摘要：Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle)-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19) or BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41) including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10). The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01). The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement) was more significant than that in the fixed-site group (85% improvement) (p < 0.01). BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U) introduced with this methodology in chronic and episodic migraines.